Atherosclerosis is an inflammatory disease; monocytes and macrophages play an important role in the progression of this disease. However, the mechanisms are not fully understood yet. Nicotinamide phosphate transferase (NAMPT) is the rate limiting enzyme in the synthesis of NAD, but extracellular NAMPT shows the characteristics of cytokines/adipokines, suggesting that it may be a link between metabolism and inflammation. In this study, we compared the expression levels of the NAMPT/NAD+/Sirt1 signaling pathway as well as NAMPT, CRP and IL-6 in the peripheral blood mononuclear cell (PBMC), and plasma in patients with acute coronary syndromes and healthy subjects, and analyzed their association with macrophage polarization. The relationship between eNAMPT and iNAMPT and the polarization of macrophages was analyzed by NAD+, NAMPT blocker, and neutralizing antibody treatment. The results showed that the expression of the NAMPT/ NAD+/Sirt1 signaling pathway was up-regulated in the peripheral blood of patients with ACS. Inhibition of iNAMPT expression can reduce M1 polarization; however, there was no significant effect on eNAMPT secretion and M2 polarization. Neutralizing eNAMPT by neutralizing antibodies can reduce M2 polarization and decrease the expression levels of IL-10, IL-13, IL-4 and IL-1ra. The addition of NAD+ in the cell culture supernatant had no significant effect on the polarization of M1 but increased the M2 polarization and the expression levels of IL-10 and IL-1ra. Our findings suggested that NAMPT is involved in the pathogenesis of atherosclerosis; the increased expression of eNAMPT in ACS patients may play a protective role by the up regulation of the NAMPT/NAD+/Sirt1 signaling pathway. (Int Heart J 2018; 59: 1116-1122 
A therosclerosis is a chronic metabolic and inflammatory disease of the vascular wall and is one of the major causes of death. 1) Acute coronary syndrome (ACS) is the main clinical manifestation of atherosclerosis; it refers to a series of clinical manifestations, including ST segment elevation myocardial infarction (STEMI), non ST segment elevation myocardial infarction (NSTEMI), and unstable angina pectoris. The accumulation of lipid and immune cells in the blood vessel wall is the characteristics of atherosclerosis. Often, ACS is associated with the partial or complete occlusion of the infarct related artery caused by the loss of atherosclerotic plaques. 2, 3) Current studies showed that inflammation and leukocytes are involved in the various stages of atherosclerosis; different types of macrophages have different phenotypes and have different effects on the occurrence, development and maintenance, or remission of inflammation. 4) Both inflammatory and anti-inflammatory macrophages are present in atherosclerotic plaques; the balance between these cell subtypes determines the fate of atherosclerotic plaques. [5] [6] [7] The polarization of macrophages is regulated by a variety of factors in atherosclerosis. However, although some studies have shown the importance of macrophage polarization in atherogenesis, the regulation process of macrophage polarization remains unclear. [8] [9] [10] Nicotinamide phosphate transferase (NAMPT) is a protein secreted by activated lymphocytes in bone marrow stromal cells, and it can synergistically stimulate the proliferation of B cells in combination with interleukin -7 (IL-7) and stem cell factor (SCF). There are two forms of NAMPT in mammals: intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT), and iNAMPT is mainly responsible for NAD+ biosynthesis; eNAMPT is associated with the role of cytokines and insulin like effects, in addition to participating in the regulation of NAD+ biosynthesis. It has been found that NAMPT is ex- pressed in lipid laden macrophages in atherosclerotic plaques; NAMPT can regulate the lipid accumulation and inflammatory state of these cells. 11) Inflammation and abnormal lipid metabolism are key factors in atherogenesis, NAMPT may be a node associated with inflammation and abnormal lipid metabolism. Increased level of NAMPT in peripheral blood is independent factor contributing to ACS, and is also a high risk factor for ischemic stroke. 12) Although a number of studies have shown that NAMPT is associated with the formation of atherosclerotic plaques, it is not known whether it is involved in the regulation of leukocytes in the peripheral blood.
NAMPT IN ACS PATIENTS
In this study, we collected peripheral blood from ACS patients and healthy controls, analyzed the differences in the plasma NAMPT levels, the cytokine levels, and the peripheral blood cell macrophage polarization in the two groups. The effect of NAMPT on the polarization of macrophages was also observed in vitro to elucidate the role of NAMPT in atherosclerosis further.
Methods
Subjects: ACS patients were recruited from the cardiothoracic surgery department, the First Affiliated Hospital of Anhui Medical University from June 2015 to Dec. 2016. All the selected patients with coronary artery disease were diagnosed by coronary angiography, coronary artery stenosis > 50%. The ACS patients included 19 cases of unstable angina pectoris (UAP), 22 cases of non ST segment elevation myocardial infarction (NSTEMI), 20 cases of ST segment elevation myocardial infarction (STEMI). The UAP patients with cardiac arrest, cardiogenic shock, hypotension or pulmonary congestion, and accompanied by malignant tumors, chronic inflammatory diseases, infection and patients who used corticosteroids were not included in this study. The normal control group included 20 age-matched cases of physical examination with no history of vascular disease. Table I shows the demographic and biochemical characteristics of the selected population. The ethics committee of Anhui Medical University has approved this study. Blood samples collection: Blood samples were collected from the ACS patients and the controls. Venous blood was collected before coronary angiography in the patients with UAP and NSTEM. The arterial blood of STEMI patients was collected when coronary angiography was performed through femoral artery catheterization or interventional therapy. PBMC isolation and culture: PBMC is separated from the buffy brown layer (buffy coats) using Isopaque-Ficoll. The cells were re-suspended with RPMI1640 medium containing 10% FBS. PBMC (1 × 10 7 ) were inoculated in 10 mm cell culture dishes and were cultured at 37 with 5% CO2 for 2 hours. The non-adherent cells were discarded and we washed them for 3 times with culture medium. They were continuously cultured with RPMI1640 containing 10% FBS, 1% penicillin -streptomycin, and 50 ng/ml M-CSF for 7d; the medium was changed every 3 days. To induce macrophages to M1 polarization, LPS of E.coli 026:B6 (100 ng/mL) and IFN-γ (20 ng/ml) were added into them and were cultured for 18 hours. To induce macrophages to M2 polarization, IL-4 (20 ng/mL) was added into them and were cultured for 18 hours. In the other groups, rNAMPT (200 ng/mL, Adipogene, San Diego, CA), NAD+ (10 μg/mL, Sigma), NAMPT inhibitor FK866 (100 nM; Axon MedChem) and NAMPT neutraliz-Zhang, ET AL 
Western blotting test:
The fresh cells were harvested and were lysed with RIPA lysis buffer on ice for 30 min with shaking at 12,000 rpm/minute. The total proteins were collected and the concentration was determined by the BCA Kit. They were analyzed with SDS-PAGE electrophoresis. Then, it was electrotransferred to the PVDF membrane. After the transmembrane, the PVDF membrane was rinsed with TBS for 10 to 15 minutes, was placed in TBS/T blocking buffer containing 5% (w/v) skimmed milk powder and was shaken at room temperature for one hour. It was incubated at 4 overnight after CD68 or CD206 (1:500), NAMPT (1:500, Abcam), Sirt1 (1:1000, Abcam) antibodies were added. Then the membrane was washed with TBST for three times (5 minutes each time). The membrane was incubated at 37 for one hour with HRP labeled secondary antibody (1:10000) diluted with TBST containing 0.05% (w/v) skimmed milk powder. It was developed with ECL for 5 minutes. The protein bands were quantified as a ratio to β-actin using Image J software. 
Results

The expression levels of eNAMPT and iNAMPT increased in patients with ACS:
We detected the levels of iNAMPT and eNAMPT in PBMC and plasma in the ACS patients and in the normal controls by fluorescent quantitative PCR and ELISA. The NAMPT mRNA levels in the UAP, NSTEMI and STEMI groups were significantly higher than those in the control group ( Figure 1A) . The results of the ELISA also showed that plasma eNAMPT levels in the control were significantly lower than those in the other ACS groups ( Figure 1B) ; plasma hsCRP and IL-6 levels of in patients with ACS were significantly higher than those in the controls ( Figure 1C, D) . The levels of NAMPT, NAD+ and SIRT1 in peripheral blood of patients with ACS were up-regulated: NAMPT is the rate limiting enzyme in NAD+ synthesis, and NAD+ is the substrate of SIRT1. In this study we found that the levels of NAMPT, NAD+ and SIRT1 in the peripheral blood of patients with ACS were up-regulated ( Figure 1E , 1F, and 1G), which suggested that the NAMPT/NAD+/SIRT1 signaling pathway is up-regulated. Levels of NAMPT mRNA and eNAMPT in M1 and M2 macrophages: RT-PCR results showed that NAMPT mRNA levels in the M1 macrophages were higher than those of the M2 macrophages. The eNAMPT level in the culture supernatant of the M2 macrophage was higher than that of the M1 macrophage supernatant (Figure 2 ). The effect of inhibiting iNAMPT and eNAMPT on the polarization of macrophages: Treatment with inhibitors FK866 could reduce the level of M1 polarization, downregulate CD68 expression, and decrease the secretion levels of inflammatory cytokines TNF-α and IL-6. Neutralizing eNAMPT with neutralizing antibodies can reduce the polarization levels of M2, and decrease the CD206 expression level and the secretion levels of IL-1ra and IL-10. Increasing the levels of NAMPT and NAD+ in the medium does not affect M1 polarization and the expression of TNF-and IL-6, but could promote the M2 polarization and the secretion of L-1ra and IL-10 ( Figure 3 ).
Discussion
It has been found that the expression of NAMPT is increased in symptomatic carotid atherosclerotic plaques, 11) increased serum NAMPT levels are associated with recent ischemic cerebrovascular events associated with carotid atherosclerosi. 13) In this study, we found that NAMPT is expressed not only in atherosclerotic plaques, but also it increased in the PBMC and the plasma in the patients with ACS compared with the normal subjects. Moreover, the expression of extracellular NAMPT (eNAMPT) was related to the M2 polarization of peripheral blood macrophages in patients with ACS; eNAMPT is associated with immunosuppressive M2 macrophages. eNAMPT can promote the macrophages cultured in vitro to express cell surface molecular markers related with M2 differentiation and secret immunoregulatory cytokines and chemokines. These results suggested that eNAMPT is involved in the polarization phenotype regulation of the monocyte/macrophage system and participates in the progression of carotid atherosclerotic plaques in ACS patients.
Macrophages have strong plasticity and can be transformed directly into proinflammatory and anti-NAMPT IN ACS PATIENTS inflammatory phenotypes, which were called M1 macrophages and M2 macrophages, respectively. M1/M2 cells were involved in the whole process of atherosclerosis. Macrophages are constantly increasing and are polarized into M1 or M2 macrophages in accordance with the progression of atherosclerosis and the condition of the disease during the development of atherosclerosis. Type M1 macrophages are mainly found in unstable plaques, whereas type M2 macrophages increase in the stable plaques.
14) Type M1 macrophages secrete proinflammatory cytokines, such as TNF-α, IL-6 and IL-12. [15] [16] [17] In contrast to M1, the M2 macrophages secrete anti-inflammatory factors such as IL-10, IL-13, IL-4 and IL-1ra, and they can promote angiogenesis and tissue remodeling and repair. [18] [19] [20] In the advanced stage of atherosclerosis, Th2 type cytokines are present in the plasma of patients. These cytokines can activate type M2 macrophages and promote the formation of fibrous caps, thereby enhancing plaque stability. 21) There are two forms of NAMPT: intracellular NAMPT ( iNAMPT ) and extracellular NAMPT (eNAMPT), which mediate different cytokines and enzyme activities. iNAMPT is the rate limiting enzyme of NAD synthesis in the intracellular salvage pathway; its mechanism involved cell metabolism activity and the interaction of different intracellular signaling pathways, such as deacetylation. 22) However, the mechanism of action of eNAMPT is unclear. When macrophages were polarized toward M1, the expression of iNAMPT was up-regulated and the amount of eNAMPT secreted was also increased. If the expression of iNAMPT is inhibited, it can reduce the polarization of macrophages to M1, but it cannot affect the secretion of eNAMPT, which suggested that eNAMPT and iNAMPT have no functional synergy. Audrito reported that eNAMPT could promote macrophages to M2 polarization in patients with chronic lymphocytic leukemia. 23) In this study; we found that the levels of iNAMPT and eNAMPT secretion were significantly increased in the patients with ACS compared with the normal controls, which was consistent with the findings in patients with coronary artery disease (CAD).
24) The expression levels of NAD+, CRP and IL-6 levels in plasma of ACS patients and SIRT1 level in PBMC were higher than those in the control group, which suggesting that the up-regulation of the NAMPT/NAD+/SIRT1 signaling pathways may contribute to the inflammatory response. A study showed that NAMPT promoted the synthesis of NAD+ and activates the post transcriptional modification of SIRT on TNF molecules and promotes the expression of IL-6.
25) The proportion of M2 macrophages in peripheral blood macrophages was higher than the M1 macrophages in the patients with ACS. The NAMPT mRNA expression was increased when the macrophages were polarized to M1 and M2 in vitro studies. Inhibition of iNAMPT expression can reduce M1 polarization and decrease the expression levels of TNF-α and IL-6; however, there was no significant effect on the eNAMPT secretion and M2 polarization. Neutralizing eNAMPT with antibodies could reduce M2 polarization and decrease expression levels of IL-10, IL-13, IL-4 and IL-1ra, which suggested that eNAMPT had the ability to promote macrophages to M2 polarization.
The study showed that the expression of NAMPT was up-regulated in cardiovascular disease patients; 24) however, whether it is useful or harmful is not clear. Study has shown that the down-regulation of NAMPT expression in ApoE knockout mice can promote the reverse cholesterol transport in macrophages through PPARα-LXRα-ABCA1/G1 signaling pathway and has an antiatherosclerotic effect. 26) However, another study showed that the overexpression of NAMPT in leukocytes in atherosclerotic patients can inhibit atherosclerosis by the regulation of PPARγ dependent monocyte differentiation. 27) The results of this study showed that the levels of iNAMPT and Sirt1 in PBMC and NAD+, eNAMPT in plasma increased in the ACS patients, which suggested that the NAMPT/NAD+/Sirt1 signaling pathway was upregulated in the ACS patients. Sirt1 is a histone deacetylase that depends on NAD+; it has the function of inhibiting apoptosis, inhibiting inflammatory reaction, and inhibiting oxidative stress injury. [28] [29] [30] [31] [32] This study also showed that iNAMPT was associated with M1 polarization in the ACS patients, whereas eNAMPT has the ability to promote macrophage polarization to M2. Fiber cap thickness was negatively correlated with CD86/CD163 ratio in the study of human arterial stiffness. [28] [29] [30] Given the distinct ways in which iNAMPT and eNAMPT work, more detailed studies are needed to determine their role in ACS patients.
In summary, in this study we found that expression levels of NAMPT in PBMC and plasma of ACS patients were higher than that in the normal subjects. NAMPT is associated with macrophage polarization in patients with ACS. eNAMPT may have the function of promoting macrophages to M2 polarization. Nevertheless, the role and regulatory mechanism of eNAMPT need to be studied further.
Disclosures
Conflicts of interest: None.
